Tirzepatide improved blood sugar control without increasing dangerous lows in type 2 diabetes patients on hemodialysis.
Time in range: 42.7% → 50.8%Hemodialysis patients spent significantly more time with healthy blood sugar levels after switching to tirzepatide
What the researchers found
Switching from dulaglutide (a single GLP-1 agonist) to tirzepatide (a dual GIP/GLP-1 agonist) in 14 hemodialysis patients with type 2 diabetes significantly improved blood sugar control. Time in range increased from 42.7% to 50.8% (p=0.02), time above range dropped from 48.4% to 37.8% (p=0.02), and mean glucose fell from 156.6 to 137.4 mg/dL (p=0.006). Critically, hypoglycemia did not increase — time below range was statistically unchanged at 11.3% vs 8.9% (p=0.75). Side effects were mild: 21.4% had dyspepsia and 7.1% had nausea, with no serious adverse events.
Why it matters
Hemodialysis patients with diabetes are among the hardest to manage — their kidney failure alters drug metabolism, and blood sugar swings during dialysis create dangerous highs and lows. Most incretin drug trials exclude these patients. This study provides rare real-world evidence that tirzepatide can safely improve glycemic control in this underserved population.
The numbers in context
TIR: 42.7%→50.8% (p=0.02); TAR: 48.4%→37.8% (p=0.02); mean glucose: 156.6→137.4 mg/dL (p=0.006); TBR: 11.3% vs 8.9% (p=0.75)
How the study worked
Single-center retrospective study using continuous glucose monitoring (CGM) in 14 type 2 diabetes patients undergoing hemodialysis who were switched from dulaglutide to tirzepatide. Glucose metrics were compared before and after the transition.
Who was studied
14 adults with type 2 diabetes undergoing hemodialysis (mean age 61.9, 11 male/3 female)
What this study cannot tell us
Very small sample of only 14 patients at a single center. Retrospective design limits the ability to control for confounders. No long-term follow-up data. The study lacks a control group that stayed on dulaglutide.
How to read the evidence
A very small (n=14), single-center, retrospective study. While the CGM data is rigorous and the results are statistically significant, the tiny sample and lack of randomization place this at a preliminary evidence level.
When this study was published
Published in 2024, this is among the earliest studies examining tirzepatide specifically in hemodialysis patients — a population largely excluded from pivotal trials.
The bigger picture
Tirzepatide's dual GIP/GLP-1 mechanism has shown superior results over single-agonist drugs in general populations, but data in kidney failure patients is scarce. This small study begins to fill that evidence gap, suggesting that the benefits of dual agonism may extend to dialysis patients without added safety risks.
Questions still open
- Would larger randomized trials confirm these benefits in hemodialysis patients?
- How does tirzepatide's dual mechanism specifically interact with the altered metabolism of dialysis patients?
- Could tirzepatide reduce cardiovascular events in this high-risk population over time?
Common questions
Why is managing diabetes harder in dialysis patients?
What's the difference between dulaglutide and tirzepatide?
Read the original research
Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.
Frontiers in pharmacology, 15, 1362242
Citation
Otsuka, Emiko; Kitamura, Mineaki; Funakoshi, Satoshi; Mukae, Hiroshi; Nishino, Tomoya. (2024). Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis.. Frontiers in pharmacology, 15, 1362242. https://doi.org/10.3389/fphar.2024.1362242